Studies in transgenic mouse models show that Wnt-5a can act as an activator of AR-mediated prostate cancer growth and Wnt-5a-mediated activation of β-catenin signaling can cooperate with Pten loss to drive AR-independent CRPC [18, 26]. Here, WNT5A is linked to prostate carcinoma.